Literature DB >> 19002475

Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease.

Takahiro Takeda1, Toshiki Uchihara, Nobutaka Arai, Toshio Mizutani, Makoto Iwata.   

Abstract

The hippocampal involvement in amyotrophic lateral sclerosis (ALS) patients has been known for more than a decade, however, its relationship to clinical manifestations including memory deficits and topographical differentiation from Alzheimer disease (AD) remain unclear. In order to clarify the anatomopathological features in the hippocampus and their relevance to disease-specific memory deficits in ALS patients, topography and cytopathology of the hippocampal lesions along the perforant pathway were quantitatively and semiquantitatively surveyed in 14 ALS patients with extramotor involvement. These pathological findings were compared with clinical characteristics assessed from their clinical records. Cytoplasmic inclusions initially appear in the granular cells of the dentate gyrus (DG) and superficial small neurons of the transentorhinal cortex (TEC) with mild subicular degeneration (stage I: inclusion stage). Subsequent gliosis and neuronal loss of the TEC, concomitant with presynaptic degeneration of the outer molecular layer of the DG, suggests an extension of the degeneration through the perforant pathway (stage II: early perforant stage). In a more advanced stage, the presynaptic degeneration is more evident with moderate to severe neuronal loss in the TEC (stage III: advanced perforant stage). This advanced stage was associated with episodic memory deficits mimicking AD in some ALS patients. This ALS pathology initiated by cytoplasmic inclusions and neuronal loss in layer II-III of the TEC is different from neurofibrillary tangles of AD, dominant in layer II-III of the entorhinal cortex. Because this involvement of the TEC-molecular DG projection and subiculum is specific to ALS, it will provide a basis for clinical characterization of memory deficits of ALS, which could be distinct from those of AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002475     DOI: 10.1007/s00401-008-0447-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  26 in total

1.  Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography.

Authors:  Robert Steinbach; Kristian Loewe; Joern Kaufmann; Judith Machts; Katja Kollewe; Susanne Petri; Reinhard Dengler; Hans-Jochen Heinze; Stefan Vielhaber; Mircea Ariel Schoenfeld; Christian Michael Stoppel
Journal:  J Neurol       Date:  2015-07-10       Impact factor: 4.849

2.  Diffusion tensor MRI changes in gray structures of the frontal-subcortical circuits in amyotrophic lateral sclerosis.

Authors:  Gaetano Barbagallo; Giuseppe Nicoletti; Andrea Cherubini; Maria Trotta; Tiziana Tallarico; Carmelina Chiriaco; Rita Nisticò; Dania Salvino; Francesco Bono; Paola Valentino; Aldo Quattrone
Journal:  Neurol Sci       Date:  2014-01-17       Impact factor: 3.307

3.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-01-01       Impact factor: 17.088

4.  Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis.

Authors:  Ryan Vass; Emily Ashbridge; Felix Geser; William T Hu; Murray Grossman; Dana Clay-Falcone; Lauren Elman; Leo McCluskey; Virginia M Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Alice S Chen-Plotkin
Journal:  Acta Neuropathol       Date:  2010-11-23       Impact factor: 17.088

5.  Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus.

Authors:  Robert D Dayton; David B Wang; Cooper D Cain; Lisa M Schrott; Julio J Ramirez; Michael A King; Ronald L Klein
Journal:  Exp Neurol       Date:  2011-12-09       Impact factor: 5.330

6.  Hippocampal connectivity in Amyotrophic Lateral Sclerosis (ALS): more than Papez circuit impairment.

Authors:  Francesca Trojsi; Federica Di Nardo; Giuseppina Caiazzo; Mattia Siciliano; Giulia D'Alvano; Teresa Ferrantino; Carla Passaniti; Dario Ricciardi; Sabrina Esposito; Luigi Lavorgna; Antonio Russo; Simona Bonavita; Mario Cirillo; Gabriella Santangelo; Fabrizio Esposito; Gioacchino Tedeschi
Journal:  Brain Imaging Behav       Date:  2020-10-23       Impact factor: 3.978

Review 7.  Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related Tauopathy.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Continuum (Minneap Minn)       Date:  2019-02

8.  Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.

Authors:  Jordi A Matías-Guiu; Vanesa Pytel; María Nieves Cabrera-Martín; Lucía Galán; María Valles-Salgado; Antonio Guerrero; Teresa Moreno-Ramos; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-04       Impact factor: 9.236

9.  Deletion of the endogenous TrkB.T1 receptor isoform restores the number of hippocampal CA1 parvalbumin-positive neurons and rescues long-term potentiation in pre-symptomatic mSOD1(G93A) ALS mice.

Authors:  Eros Quarta; Gianluca Fulgenzi; Riccardo Bravi; Erez James Cohen; Sudhirkumar Yanpallewar; Lino Tessarollo; Diego Minciacchi
Journal:  Mol Cell Neurosci       Date:  2018-03-24       Impact factor: 4.314

10.  Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.

Authors:  Johnathan Cooper-Knock; Christopher Hewitt; J Robin Highley; Alice Brockington; Antonio Milano; Somai Man; Joanne Martindale; Judith Hartley; Theresa Walsh; Catherine Gelsthorpe; Lynne Baxter; Gillian Forster; Melanie Fox; Joanna Bury; Kin Mok; Christopher J McDermott; Bryan J Traynor; Janine Kirby; Stephen B Wharton; Paul G Ince; John Hardy; Pamela J Shaw
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.